Clinic
Indiana University Health Ball Memorial Hospital, INC.
Indiana University Health Ball Memorial Hospital, INC. was paid $44.54M by Medicaid between Jan 2018 and Nov 2024, across 211 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoINDIANA UNIVERSITY HEALTH BALL MEMORIAL HOSPITAL, INC.
MUNCIE, IN 47303
MUNCIE, IN 47303
33aNPI1225195340assigned 01/02/2007
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$44.54M
24GClaims804,468
24DCodes billed211
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Indiana
Rank by total paid#1 of 87
Median peer was paid$115K
This provider vs. median387×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 144,491 | $2.58M | |
| 2019 | 107,163 | $4.91M | |
| 2020 | 90,133 | $4.96M | |
| 2021 | 113,605 | $7.45M | |
| 2022 | 147,702 | $9.52M | |
| 2023 | 124,878 | $9.10M | |
| 2024incomplete | 76,496 | $6.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 41,402 | 36,965 | $5.88M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 38,520 | 35,258 | $5.82M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 12% | 41,736 | 36,613 | $5.43M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 11% | 10,926 | 3,565 | $4.97M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 7.9% | 1,770 | 1,603 | $3.52M |
| 71045 | Radiologic examination, chest; single view | 4.9% | 16,697 | 14,607 | $2.20M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.3% | 35,561 | 31,211 | $1.92M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 3.9% | 28,293 | 24,419 | $1.75M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.9% | 3,997 | 3,475 | $1.30M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.1% | 12,395 | 7,598 | $928K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 1.7% | 5,456 | 4,640 | $736K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.6% | 19,936 | 17,104 | $707K |
199 more codes
| 95811 | 1.3% | 327 | $574K | |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 6,421 | $536K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 3,015 | $502K |
| 99213 | Doctor's office visit, returning patient (routine) | 1.1% | 6,108 | $482K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 5,078 | $410K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 90,217 | $383K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,250 | $370K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 3,877 | $357K |
| 80320 | <1% | 3,555 | $344K | |
| 80053 | Comprehensive metabolic panel | <1% | 54,272 | $336K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 9,497 | $324K |
| 59025 | Fetal non-stress test | <1% | 1,134 | $297K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 3,550 | $282K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 6,389 | $269K |
| 36415 | Collection of venous blood by venipuncture | <1% | 75,659 | $254K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 1,289 | $161K |
| 99218 | <1% | 246 | $129K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 180 | $128K |
| 84484 | <1% | 22,873 | $128K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 716 | $122K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,485 | $121K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,644 | $116K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,826 | $115K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 936 | $110K |
| 87503 | <1% | 4,182 | $100K | |
| 36591 | <1% | 1,422 | $96K | |
| 95806 | <1% | 283 | $95K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,456 | $88K |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 820 | $67K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,164 | $66K |
| 81025 | <1% | 11,717 | $63K | |
| 77336 | <1% | 565 | $62K | |
| 99221 | <1% | 110 | $61K | |
| 76801 | <1% | 476 | $61K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12,675 | $59K |
| 62323 | <1% | 107 | $58K | |
| 76818 | <1% | 615 | $57K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 954 | $57K |
| 80348 | <1% | 384 | $55K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 717 | $52K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 849 | $51K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,953 | $51K |
| 80050 | General health panel | <1% | 451 | $49K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 629 | $48K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,837 | $47K |
| 83690 | <1% | 15,656 | $47K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,239 | $44K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,912 | $44K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,766 | $41K |
| 80061 | Lipid panel | <1% | 4,652 | $40K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 391 | $39K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 878 | $33K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 358 | $33K |
| 87660 | <1% | 2,174 | $33K | |
| 87510 | <1% | 2,174 | $33K | |
| 87480 | <1% | 2,174 | $33K | |
| 80076 | <1% | 8,642 | $32K | |
| 76813 | <1% | 407 | $31K | |
| 80047 | <1% | 8,763 | $31K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 919 | $30K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,659 | $28K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 130 | $26K |
| 81001 | <1% | 16,289 | $25K | |
| 83880 | <1% | 1,188 | $23K | |
| 43249 | <1% | 19 | $21K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,166 | $20K |
| 81003 | <1% | 14,059 | $20K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 64 | $19K |
| 76820 | <1% | 447 | $19K | |
| 83735 | <1% | 4,683 | $19K | |
| 77334 | <1% | 131 | $19K | |
| 83605 | <1% | 2,814 | $18K | |
| 87522 | Neg quan hep c or qual rna | <1% | 757 | $17K |
| 85379 | <1% | 2,425 | $15K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,791 | $14K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 22 | $14K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 879 | $14K |
| 80305 | <1% | 1,259 | $13K | |
| 86317 | <1% | 1,042 | $12K | |
| 86803 | <1% | 1,090 | $12K | |
| 82607 | <1% | 1,209 | $11K | |
| 85014 | <1% | 13,564 | $10K | |
| 82728 | <1% | 1,291 | $10K | |
| 87340 | <1% | 1,639 | $10K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 735 | $10K |
| 99201 | <1% | 192 | $9K | |
| 86780 | <1% | 899 | $9K | |
| 87276 | <1% | 1,573 | $9K | |
| 87275 | <1% | 1,573 | $8K | |
| 86140 | <1% | 2,468 | $8K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 346 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 890 | $8K |
| 92526 | <1% | 49 | $7K | |
| 87902 | <1% | 83 | $7K | |
| 62370 | <1% | 71 | $6K | |
| 82746 | <1% | 701 | $6K | |
| 83550 | <1% | 1,297 | $6K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 338 | $6K |
| 84702 | <1% | 641 | $6K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 40 | $6K |
| 86850 | <1% | 1,086 | $5K | |
| 83540 | <1% | 1,302 | $5K | |
| 80349 | <1% | 109 | $5K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 30 | $4K |
| 74018 | <1% | 24 | $4K | |
| 88142 | <1% | 331 | $4K | |
| 84704 | <1% | 676 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 336 | $4K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 78 | $4K |
| 84144 | <1% | 178 | $3K | |
| 86762 | <1% | 241 | $3K | |
| 85610 | <1% | 1,497 | $3K | |
| 97162 | <1% | 25 | $3K | |
| 97113 | <1% | 37 | $3K | |
| 20610 | <1% | 16 | $3K | |
| 86706 | <1% | 417 | $3K | |
| 82951 | <1% | 245 | $3K | |
| 86900 | <1% | 1,178 | $3K | |
| 73110 | <1% | 44 | $3K | |
| 86901 | <1% | 1,178 | $3K | |
| 86704 | <1% | 368 | $3K | |
| 73610 | <1% | 62 | $2K | |
| 86708 | <1% | 321 | $2K | |
| 82947 | <1% | 2,947 | $2K | |
| 84163 | <1% | 373 | $2K | |
| 82330 | <1% | 2,596 | $2K | |
| 82803 | <1% | 177 | $2K | |
| 97161 | <1% | 13 | $2K | |
| 87428 | <1% | 77 | $2K | |
| 82105 | <1% | 205 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 122 | $2K |
| 82677 | <1% | 88 | $2K | |
| 82565 | <1% | 2,878 | $2K | |
| 77300 | <1% | 15 | $1K | |
| 85730 | <1% | 397 | $1K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 39 | $1K |
| 85027 | <1% | 274 | $1K | |
| 82150 | <1% | 285 | $1K | |
| 83970 | <1% | 79 | $1K | |
| 85652 | <1% | 964 | $1K | |
| 84132 | <1% | 2,598 | $1K | |
| 84295 | <1% | 2,554 | $1K | |
| 82784 | <1% | 233 | $1K | |
| 86336 | <1% | 88 | $1K | |
| 83516 | <1% | 182 | $991.05 | |
| 84520 | <1% | 2,602 | $988.30 | |
| 82043 | <1% | 274 | $960.27 | |
| 82570 | <1% | 301 | $932.00 | |
| 82435 | <1% | 2,546 | $916.78 | |
| 82731 | <1% | 56 | $864.21 | |
| 84439 | <1% | 180 | $857.19 | |
| 82374 | <1% | 2,453 | $843.94 | |
| 83883 | <1% | 167 | $842.70 | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 30 | $829.36 |
| 87070 | <1% | 2,762 | $803.22 | |
| 83010 | <1% | 167 | $738.10 | |
| 84100 | <1% | 272 | $634.55 | |
| 82977 | <1% | 167 | $452.66 | |
| 87536 | <1% | 13 | $407.64 | |
| 87040 | <1% | 83 | $395.26 | |
| 84460 | <1% | 411 | $349.90 | |
| 87205 | <1% | 2,711 | $341.87 | |
| 82172 | <1% | 167 | $341.55 | |
| 73630 | <1% | 18 | $306.63 | |
| 85018 | <1% | 323 | $261.34 | |
| 86225 | <1% | 142 | $246.24 | |
| 82465 | <1% | 161 | $237.38 | |
| 87077 | <1% | 644 | $224.98 | |
| 86039 | <1% | 139 | $161.80 | |
| 82010 | <1% | 30 | $158.35 | |
| 84480 | <1% | 14 | $143.33 | |
| 86200 | <1% | 143 | $141.09 | |
| 82247 | <1% | 148 | $137.40 | |
| 86308 | <1% | 19 | $95.28 | |
| 87186 | <1% | 422 | $91.98 | |
| 80069 | <1% | 35 | $81.12 | |
| 83615 | <1% | 18 | $79.53 | |
| 82550 | <1% | 101 | $55.39 | |
| 86431 | <1% | 126 | $55.02 | |
| 82950 | <1% | 12 | $52.25 | |
| 84550 | <1% | 12 | $42.60 | |
| 87210 | <1% | 29 | $39.48 | |
| J3490 | Unclassified drugs | <1% | 293 | $38.63 |
| 82948 | <1% | 233 | $33.44 | |
| 82553 | <1% | 21 | $16.26 | |
| 99459 | 0% | 135 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 81 | $0.00 |
| A0428 | Ambulance service, basic life support, non-emergency transport, (bls) | 0% | 331 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 534 | $0.00 |
| 0064U | 0% | 145 | $0.00 | |
| C1755 | Catheter, intraspinal | 0% | 52 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 42 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 304 | $0.00 |
| A0427 | Emergency ambulance ride, advanced life support | 0% | 39 | $0.00 |
| 0065U | 0% | 16 | $0.00 | |
| A0425 | Ground mileage, per statute mile | 0% | 699 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 279 | $0.00 |
| 86235 | 0% | 26 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 160 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialVANATOR, JON (CFO)